na17.a2 peptide
Vaccineexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2002 (NCT00036816)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
- Melanoma cellsImmunity, active
immunity, active - melanoma cells
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- na17.a2
- na17.a2 peptide
- na17.a2 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01723813 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2012 | Université catholique de Louvain |
| NCT01307618 | Phase 2 | Feb 1, 2011 | National Cancer Institute (NCI), University of Chicago |
| NCT01191034 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2010 | Université catholique de Louvain |
| NCT00036816 | Phase 3 | Feb 1, 2002 | European Organisation for Research and Treatment of Cancer, Université catholique de Louvain, University of Copenhagen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Université catholique de Louvain | Academic/Hospital | 3 | 2 | 2 | 2002 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2011 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2002 |
5 organizations
Page 1 / 1